5
Participants
Start Date
January 14, 2020
Primary Completion Date
July 31, 2023
Study Completion Date
July 31, 2023
Eculizumab
Following a weight-based weekly dose of eculizumab during an induction phase, participants will receive weight-based doses of eculizumab every 2 weeks during the Primary Treatment Period and Extension Treatment Period.
Research Site, Esplugues de Llobregat
Research Site, New York
Research Site, Genova
Clinical Trial Site, Philadelphia
Clinical Trial Site, Washington D.C.
Clinical Trial Site, Rockville
Research Site, Gallarate
Research Site, Baltimore
Clinical Trial Site, Chapel Hill
Clinical Trial Site, Atlanta
Clinical Trial Site, Miami
Research Site, Datteln
Research Site, Münster
Research Site, St Louis
Research Site, Dallas
Clinical Trial Site, San Francisco
Research Site, Catania
Clinical Trial Site, Boston
Research Site, Boston
Research Site, Hackensack
Research Site, New Brunswick
Research Site, Calgary
Clinical Trial Site, Edmonton
Clinical Trial Site, Toronto
Clinical Trial Site, Regensburger Straße
Clinical Trial Site, Genoa
Clinical Trial Site, Rome
Clinical Trial Site, Yokohama
Clinical Trial Site, Seoul
Clinical Trial Site, Barcelona
Clinical Trial Site, Seville
Research Site, Toronto
Research Site, Montreal
Research Site, Rome
Research Site, Yokohama
Lead Sponsor
Alexion Pharmaceuticals, Inc.
INDUSTRY